Pancreatic Cancer Research

ResearcherUniversity of CologneActive in the last 2 years

Alexander Quaas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3537-6011; OpenAlex author ID A5045953059. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers

Papers 15

  1. LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming. Co-author DOI 10.1038/s41419-026-09075-4↗
  2. Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. Co-author DOI 10.1038/s41467-026-73189-8↗
  3. MTAP-Deficiency Identifies a Myofibroblastic and Immune-Attenuated Tumor Microenvironment Subtype in Pancreatic Ductal Adenocarcinoma Last author DOI 10.21203/rs.3.rs-10656530/v1↗
  4. Tertiary Lymphoid Structures in Pancreatic Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones with Secondary Lymphoid Organs,… Co-author DOI 10.1158/2326-6066.cir-24-0299↗
  5. Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-024-05681-x↗
  6. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Co-author DOI 10.1016/j.tranon.2024.102044↗
  7. Multiparametric Characterization of the DSL-6A/C1 Pancreatic Cancer Model in Rats. Co-author DOI 10.3390/cancers16081535↗
  8. Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. Co-author DOI 10.1007/s00432-023-04702-5↗
  9. Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15072049↗
  10. Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13112689↗
  11. IL-17B/RB Activation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Metabolism and Growth. Co-author DOI 10.3390/cancers13215338↗
  12. Proposal for a definition of "Oligometastatic disease in pancreatic cancer". Co-author DOI 10.1186/s12885-019-6448-9↗
  13. First reported case of a collision tumor composed of pancreatic adenocarcinoma and retroperitoneal liposarcoma: a case report. Co-author DOI 10.1186/s12885-018-5151-6↗
  14. Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target. Last author DOI 10.3892/mco.2017.1194↗
  15. Infiltration of peritumoural but tumour-free parenchyma with IgG4-positive plasma cells in hilar cholangiocarcinoma and pancreatic adenocarcinoma. First author DOI 10.1016/j.dld.2013.03.007↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christiane J. Bruns · 11 shared papers, 2018–2026 · strength 1.83
  2. Felix Popp · 9 shared papers, 2019–2026 · strength 1.48
  3. Yue Zhao · 6 shared papers, 2021–2026 · strength 0.97
  4. Su Ir Lyu · 5 shared papers, 2023–2026 · strength 0.97
  5. Karl Knipper · 5 shared papers, 2023–2026 · strength 0.97
  6. Alexander Ioannis Damanakis · 6 shared papers, 2019–2024 · strength 0.90
  7. Thomas Schmidt · 3 shared papers, 2023–2024 · strength 0.48
  8. Maximilian Reichert · 2 shared papers, 2026 · strength 0.45
  9. Hans Schlößer · 2 shared papers, 2024–2025 · strength 0.38
  10. Dirk Waldschmidt · 3 shared papers, 2017–2024 · strength 0.36
  11. Zhefang Wang · 2 shared papers, 2021–2026 · strength 0.36
  12. Philipp Lohneis · 2 shared papers, 2021–2025 · strength 0.31
  13. Heike Löser · 3 shared papers, 2017–2021 · strength 0.29
  14. Julian Karlbauer · 1 shared paper, 2026 · strength 0.29
  15. Werner Hartwig · 2 shared papers, 2023–2024 · strength 0.29
  16. Utz Settmacher · 2 shared papers, 2023–2024 · strength 0.29
  17. Bettina Rau Rau · 2 shared papers, 2023–2024 · strength 0.29
  18. Jiangang Zhao · 1 shared paper, 2026 · strength 0.25
  19. Qiongzhu Dong · 1 shared paper, 2026 · strength 0.25
  20. Hana Algül · 1 shared paper, 2026 · strength 0.25
  21. Jiahui Li · 2 shared papers, 2021 · strength 0.23
  22. Moritz Reese · 1 shared paper, 2026 · strength 0.20
  23. Sofya Tishina · 1 shared paper, 2026 · strength 0.20
  24. Anna Trauzold · 1 shared paper, 2026 · strength 0.20
  25. Janine Murr · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.